{"symbol":"LLY","fiscalQuarter":"Q2-2026","reportDate":"2026-08-05","reportTime":"BMO","status":"upcoming","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q2-2026","preBrief":{"companySnapshot":"Eli Lilly and Company (LLY) is a leading pharmaceutical company focused on developing innovative medicines to treat various health conditions. With a market cap of $861 billion, it plays a significant role in the healthcare sector, particularly in diabetes, oncology, and immunology.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to expand its market share and drive sales, crucial for sustaining long-term growth.","consensus":"N/A"},{"name":"Market Share in Key Therapeutic Areas","why":"Understanding market share in diabetes and oncology helps gauge competitive positioning and future revenue potential.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Eli Lilly reported an EPS of $8.55, exceeding estimates by 21.07%. The stock reacted positively, gaining 9.80% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Overall expectations for Eli Lilly's upcoming earnings are mixed, with investors hoping for continued strong performance but wary of potential challenges.","bullCase":"If Eli Lilly continues to exceed EPS expectations, it could signal robust demand for its products and strong operational efficiency.","bearCase":"Conversely, any signs of slowing revenue growth or increased competition in its key markets could lead to a negative reaction from investors."},"optionsSignal":{"impliedMove":"9.78%","context":"The options market is pricing in a significant potential move, suggesting that investors anticipate volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+21.07%","reaction":"+9.80%"},{"quarter":"Q4-2025","epsSurprise":"+7.88%","reaction":"+10.33%"},{"quarter":"Q3-2025","epsSurprise":"+16.59%","reaction":"+3.81%"},{"quarter":"Q2-2025","epsSurprise":"+14.08%","reaction":"-14.14%"},{"quarter":"Q1-2025","epsSurprise":"-5.01%","reaction":"-11.66%"}],"pivotalQuestions":[{"question":"What will the EPS be for Q2-2026?","whyItMatters":"The EPS figure will be critical in determining if the company can maintain its strong performance and investor confidence."},{"question":"How is Eli Lilly addressing competition in its key therapeutic areas?","whyItMatters":"Insights into competitive strategies will help investors understand potential risks to revenue growth and market share."}],"thesisBreakLevels":{"bullTrigger":"A reported EPS of $9.00 or higher would confirm strong demand and operational efficiency.","bearTrigger":"An EPS below $7.50 could indicate challenges in maintaining profitability and growth.","context":"This quarter's performance is under scrutiny as investors weigh the company's ability to sustain its recent success against competitive pressures."},"scenarioPlaybook":{"beatAndRaise":"If Eli Lilly beats expectations, history suggests the stock could rise by around 3.77%, confirming strong operational performance.","inLineCautious":"A cautious in-line report may lead to muted stock movement as investors digest management's commentary.","miss":"If the company misses expectations, history suggests a potential decline of about 8.97%, raising concerns about future growth."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the impact of Eli Lilly's recent product launches, which could drive higher-than-expected revenue growth.","supportingPoints":["Eli Lilly's recent EPS surprises indicate strong operational performance, suggesting a trend that may continue.","The options market is pricing in a significant move, indicating that investors expect volatility that could favor a positive outcome."],"riskToConsensus":"If the company announces significant new partnerships or product approvals, it could shift market sentiment dramatically."},"whatToListenFor":["Updates on new product launches and their market reception.","Any changes in guidance regarding revenue growth in key therapeutic areas.","Insights into competitive pressures and market share dynamics.","Management's commentary on cost management and operational efficiency.","Details on upcoming clinical trials and their potential impact on future revenue."],"metaDescription":"Eli Lilly (LLY) reports Q2 2026 earnings August 5. Investors are keen to see if EPS exceeds expectations amid competitive pressures."}}